Table of Contents Author Guidelines Submit a Manuscript
Cardiology Research and Practice
Volume 2012, Article ID 645469, 13 pages
http://dx.doi.org/10.1155/2012/645469
Research Article

Long-Term Costs of Ischemic Stroke and Major Bleeding Events among Medicare Patients with Nonvalvular Atrial Fibrillation

1Center for Epidemiology and Database Analytics, United BioSource Corporation, 7101 Wisconsin Avenue, Suite 600, Bethesda, MD 20814, USA
2Health Economics and Outcomes Research, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA
3Economic Analysis and Solutions, United BioSource Corporation, 7101 Wisconsin Avenue, Suite 600, Bethesda, MD 20814, USA

Received 17 May 2012; Revised 30 July 2012; Accepted 1 August 2012

Academic Editor: Natig Gassanov

Copyright © 2012 Catherine J. Mercaldi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [35 citations]

The following is the list of published articles that have cited the current article.

  • Andreas Clemens, Siyang Peng, Sarah Brand, Martina Brueckmann, Anuraag Kansal, Jonathan Lim, Herbert Noack, Stephen Sander, and Sonja Sorensen, “Efficacy and Cost-Effectiveness of Dabigatran Etexilate Versus Warfarin in Atrial Fibrillation in Different Age Subgroups,” American Journal of Cardiology, vol. 114, no. 6, pp. 849–855, 2014. View at Publisher · View at Google Scholar
  • François-Emery Cotté, Gwendoline Chaize, Isabelle Kachaner, Anne-Françoise Gaudin, Alexandre Vainchtock, and Isabelle Durand-Zaleski, “Incidence and Cost of Stroke and Hemorrhage in Patients Diagnosed with Atrial Fibrillation in France,” Journal of Stroke and Cerebrovascular Diseases, vol. 23, no. 2, pp. e73–e83, 2014. View at Publisher · View at Google Scholar
  • C. R. Lenihan, M. E. Montez-Rath, J. I. Shen, J. D. Scandling, M. P. Turakhia, T. I. Chang, and W. C. Winkelmayer, “Correlates and outcomes of warfarin initiation in kidney transplant recipients newly diagnosed with atrial fibrillation,” Nephrology Dialysis Transplantation, 2014. View at Publisher · View at Google Scholar
  • Cynthia L. Gong, and Joel W. Hay, “Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer,” JNCCN Journal of the National Comprehensive Cancer Network, vol. 12, no. 10, pp. 1417–1425, 2014. View at Publisher · View at Google Scholar
  • Louise H. Anderson, Edward J. Black, Kenneth C. Civello, Melissa S. Martinson, and David C. Kress, “Cost-effectiveness of the convergent procedure and catheter ablation for non-paroxysmal atrial fibrillation,” Journal of Medical Economics, vol. 17, no. 7, pp. 481–491, 2014. View at Publisher · View at Google Scholar
  • Michael H. Kim, Kelly F. Bell, Daniel Wiederkehr, Jay Lin, Dinara Makenbaeva, and John Graham, “Health care burden of dyspepsia among nonvalvular atrial fibrillation patients,” Journal of Managed Care Pharmacy, vol. 20, no. 4, pp. 391–399, 2014. View at Publisher · View at Google Scholar
  • Xianying Pan, Teresa A. Simon, Melissa Hamilton, and Andreas Kuznik, “Comparison of costs and discharge outcomes for patients hospitalized for ischemic or hemorrhagic stroke with or without atrial fibrillation in the Uni,” Journal Of Thrombosis And Thrombolysis, vol. 39, no. 4, pp. 508–515, 2015. View at Publisher · View at Google Scholar
  • Anand Shewale, Jill Johnson, Chenghui Li, David Nelsen, and Bradley Martin, “Variation in Anticoagulant Recommendations by the Guidelines and Decision Tools among Patients with Atrial Fibrillation,” Healthcare, vol. 3, no. 1, pp. 130–145, 2015. View at Publisher · View at Google Scholar
  • Vivek Y. Reddy, Ronald L. Akehurst, Shannon O. Armstrong, Stacey L. Amorosi, Stephen M. Beard, and David R. Holmes, “Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF Warfarin Versus NOACs Versus LAA Closure,” Journal Of The American College Of Cardiology, vol. 66, no. 24, pp. 2728–2739, 2015. View at Publisher · View at Google Scholar
  • John Condon, Vincent He, Yuejen Zhao, Paul Lawton, and Dominique A. Cadilhac, “Lifetime direct costs of stroke for indigenous patients adjusted for comorbidities,” Neurology, vol. 87, no. 5, pp. 458–465, 2016. View at Publisher · View at Google Scholar
  • Jason Shafrin, Avrita Campinha-Bacote, Jeffrey Trocio, Manan Shah, John A. Romley, Amanda Bruno, Joanna P. MacEwan, and Wilson Tan, “Physician and Patient Preferences for Nonvalvular Atrial Fibrillation Therapies,” Value in Health, vol. 19, no. 4, pp. 451–459, 2016. View at Publisher · View at Google Scholar
  • Robert O. Roswell, Brian Greet, Sunny Shah, Samuel Bernard, Alexandra Milin, Iryna Lobach, Yu Guo, Martha J. Radford, and Jeffrey S. Berger, “Intravenous heparin dosing strategy in hospitalized patients with atrial dysrhythmias,” Journal of Thrombosis and Thrombolysis, vol. 42, no. 2, pp. 179–185, 2016. View at Publisher · View at Google Scholar
  • Tim Bancroft, Jonathan Lim, Cheng Wang, Stephen D. Sander, and Jason P. Swindle, “Health Care Resource Utilization, Costs, and Persistence in Patients Newly Diagnosed as Having Nonvalvular Atrial Fibrillation and Newly Treated With ,” Clinical Therapeutics, vol. 38, no. 3, pp. 545–556, 2016. View at Publisher · View at Google Scholar
  • Siyang Peng, Kristen A. Deger, Anastasia Ustyugova, Pranav Gandhi, Nan Qiao, Cheng Wang, and Anuraag R. Kansal, “Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries,” Current Medical Research and Opinion, pp. 1–9, 2017. View at Publisher · View at Google Scholar
  • Adrienne M. Gilligan, Pranav Gandhi, Xue Song, Cheng Wang, Caroline Henriques, Stephen Sander, and David M. Smith, “All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin,” American Journal of Cardiovascular Drugs, 2017. View at Publisher · View at Google Scholar
  • S. Williamson, F. Landeiro, T. McConnell, L. Fulford-Smith, M. K. Javaid, A. Judge, and J. Leal, “Costs of fragility hip fractures globally: a systematic review and meta-regression analysis,” Osteoporosis International, 2017. View at Publisher · View at Google Scholar
  • Xue Song, Pranav Gandhi, Adrienne M. Gilligan, Prachi Arora, Cheng Wang, Caroline Henriques, Stephen Sander, and David M. Smith, “Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin,” Expert Review of Pharmacoeconomics & Outcomes Research, pp. 1–10, 2017. View at Publisher · View at Google Scholar
  • Vicki C. Tse, Lung Wai Au-Doung, Ian C.K. Wong, Esther W. Chan, and Xue Li, “The impact of ischaemic stroke on atrial fibrillation-related healthcare cost: A systematic review,” Europace, vol. 19, no. 6, pp. 937–946, 2017. View at Publisher · View at Google Scholar
  • A. Shrestha, A. Eldar-Lissai, N. Hou, D.N. Lakdawalla, and K. Batt, “Real-world resource use and costs of haemophilia A-related bleeding,” Haemophilia, 2017. View at Publisher · View at Google Scholar
  • Steven Deitelzweig, W. Richey Neuman, Brandy Menges, Melissa Lingohr-Smith, and Jay Lin, “Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors,” Journal of Medical Economics, vol. 20, no. 12, pp. 1217–1223, 2017. View at Publisher · View at Google Scholar
  • Brian Olshansky, Luc Pierard, Karen Sliwa, Irina Savelieva, Gulmira Kudaiberdieva, Jonathan Piccini, Robert Storey, Raffaele De Caterina, Sigrun Halvorsen, Diana Gorog, Andrea Rubboli, Laurent Fauchier, Francisco Marin, Joao Morais, Calambur Narasimhan, Gregory Y. H Lip, Tatjana Potpara, Nizal Sarrafzadegan, Gonzalo Varela, Gemma Vilahur, Thomas Weiss, Giuseppe Boriani, Bianca Rocca, Jean Philippe Collet, Bulent Gorenek, Christian Sticherling, Tze-Fan Chao, Francesco Violi, Mohan Nair, Leandro Zimerman, Ashley Chin, Robert Scott-Millar, Deirdre A Lane, and Torben B Larsen, “Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: A joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE),” Europace, vol. 19, no. 11, pp. 1757–1758, 2017. View at Publisher · View at Google Scholar
  • Adrienne M. Gilligan, Jessica Franchino-Elder, Xue Song, Cheng Wang, Caroline Henriques, Amy Sainski-Nguyen, Kathleen Wilson, David M. Smith, and Stephen Sander, “Comparison of all-cause costs and healthcare resource use among patients with newly-diagnosed non-valvular atrial fibrillation newly treated with oral anticoagulants,” Current Medical Research and Opinion, pp. 1–11, 2017. View at Publisher · View at Google Scholar
  • Luc Pierard, Karen Sliwa, Gemma Vilahur, Thomas Weiss, Bianca Rocca, Jean Philippe Collet, Raffaele De Caterina, Laurent Fauchier, Deirdre A. Lane, Torben B. Larsen, Francisco Marin, Joao Morais, Calambur Narasimhan, Gregory Y. H. Lip, Brian Olshansky, Tatjana Potpara, Nizal Sarrafzadegan, Gonzalo Varela, and Giuseppe Boriani, “Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE),” Thrombosis and Haemostasis, vol. 117, no. 12, pp. 2215–2236, 2017. View at Publisher · View at Google Scholar
  • Kibum Kim, Todd A. Lee, Daniel R. Touchette, Robert J. DiDomenico, Amer K. Ardati, and Surrey M. Walton, “Comparison of 6-Month Costs Between Oral Antiplatelet Agents Following Acute Coronary Syndrome,” Journal of Managed Care & Specialty Pharmacy, vol. 24, no. 8, pp. 800–812, 2018. View at Publisher · View at Google Scholar
  • Vivek Y. Reddy, Ronald L. Akehurst, Stacey L. Amorosi, Meghan B. Gavaghan, Deanna S. Hertz, and David R. Holmes, “Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non–Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation,” Stroke, vol. 49, no. 6, pp. 1464–1470, 2018. View at Publisher · View at Google Scholar
  • Chinmay G. Deshpande, Stephen Kogut, and Cynthia Willey, “Real-World Health Care Costs Based on Medication Adherence and Risk of Stroke and Bleeding in Patients Treated with Novel Anticoagulant Therapy,” Journal of Managed Care & Specialty Pharmacy, vol. 24, no. 5, pp. 430–439, 2018. View at Publisher · View at Google Scholar
  • Anthony J. Comerota, Rafael Torrejon Torres, Rhodri Saunders, Audrey Ozols, and Kwok Ming Ho, “Intermittent pneumatic compression is a cost-effective method of orthopedic postsurgical venous thromboembolism prophylaxis,” ClinicoEconomics and Outcomes Research, vol. 10, pp. 231–241, 2018. View at Publisher · View at Google Scholar
  • Tina Baykaner, Steve Duff, James T. Hasegawa, Michael S. Mafilios, and Mintu P. Turakhia, “Cost effectiveness of focal impulse and rotor modulation guided ablation added to pulmonary vein isolation for atrial fibrillation,” Journal of Cardiovascular Electrophysiology, 2018. View at Publisher · View at Google Scholar
  • Chinmay G. Deshpande, Stephen Kogut, Robert Laforge, and Cynthia Willey, “Impact of medication adherence on risk of ischemic stroke, major bleeding and deep vein thrombosis in atrial fibrillation patients using novel oral anticoagulants,” Current Medical Research and Opinion, pp. 1–8, 2018. View at Publisher · View at Google Scholar
  • Jonathan Salcedo, Joel W. Hay, and Jenny Lam, “Cost-effectiveness of rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function,” International Journal of Cardiology, 2018. View at Publisher · View at Google Scholar
  • Jessica Franchino-Elder, Cheng Wang, Caroline Henriques, Amy Sainski-Nguyen, Kathleen Wilson, David M. Smith, Stephen Sander, Adrienne M. Gilligan, and Xue Song, “Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin,” Expert Review of Pharmacoeconomics and Outcomes Research, 2018. View at Publisher · View at Google Scholar
  • Berkinbayev, Akpanova, Mussagaliyeva, Ospanova, and Zhussupov, “Clinical and demographic features of patients with stroke and atrial fibrillation,” Kardiologiya, vol. 58, pp. 48–57, 2018. View at Publisher · View at Google Scholar
  • Antonio Miceli, Lorenzo Pradelli, Massimiliano Povero, Matteo Ferrarini, Matteo Pinciroli, and Mattia Glauber, “Cost-utility of surgical sutureless bioprostheses vs TAVI in aortic valve replacement for patients at intermediate and high surgical risk,” ClinicoEconomics and Outcomes Research, vol. 10, pp. 733–745, 2018. View at Publisher · View at Google Scholar
  • Vivek Y. Reddy, Ronald L. Akehurst, Meghan B. Gavaghan, Stacey L. Amorosi, and David R. Holmes, “Cost‐Effectiveness of Left Atrial Appendage Closure for Stroke Reduction in Atrial Fibrillation: Analysis of Pooled, 5‐Year, Long‐Term Data,” Journal of the American Heart Association, vol. 8, no. 13, 2019. View at Publisher · View at Google Scholar
  • Heather M. Rozjabek, Craig I. Coleman, Veronica Ashton, François Laliberté, Paul Oyefesobi, Dominique Lejeune, Guillaume Germain, Jeff R. Schein, Zhong Yuan, Patrick Lefebvre, and Eric D. Peterson, “Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants,” Journal of Medical Economics, pp. 1–9, 2019. View at Publisher · View at Google Scholar